Expand COCP Menu
COCP MENU

COCP Latest Press Releases

-- December 18, 2025 --

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Globe Newswire 8:00 AM

-- December 1, 2025 --

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference Globe Newswire 8:00 AM

-- November 14, 2025 --

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Globe Newswire 8:00 AM

-- October 30, 2025 --

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 8:00 AM

-- October 2, 2025 --

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference Globe Newswire 8:00 AM

-- September 15, 2025 --

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Globe Newswire 4:30 PM

-- September 12, 2025 --

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Globe Newswire 9:43 AM
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference Globe Newswire 8:00 AM

-- September 8, 2025 --

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment Globe Newswire 8:00 AM

-- September 3, 2025 --

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference Globe Newswire 8:00 AM

-- August 14, 2025 --

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes